MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
11.50
-0.85 (-6.88%)
At close: Dec 5, 2025, 4:00 PM EST
11.73
+0.23 (2.00%)
After-hours: Dec 5, 2025, 5:50 PM EST
MiNK Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 5.78 | 4.31 | 7.43 | 7.83 | 4.64 | 1.29 | |
| Research & Development | 5.65 | 6.34 | 15.49 | 23.12 | 13.97 | 9.51 | |
| Other Operating Expenses | 1.01 | 0.64 | - | - | - | - | |
| Operating Expenses | 12.44 | 11.29 | 22.92 | 30.95 | 18.61 | 10.8 | |
| Operating Income | -12.44 | -11.29 | -22.92 | -30.95 | -18.61 | -10.8 | |
| Interest Expense | - | - | - | - | -2.43 | -2.44 | |
| Interest & Investment Income | 0.11 | 0.17 | 0.46 | 0.25 | - | - | |
| Currency Exchange Gain (Loss) | - | - | - | - | -0.41 | 0.49 | |
| Other Non Operating Income (Expenses) | -0.02 | 0.15 | -0 | -0.09 | 0.63 | 0.35 | |
| EBT Excluding Unusual Items | -12.36 | -10.97 | -22.46 | -30.78 | -20.82 | -12.4 | |
| Gain (Loss) on Sale of Assets | - | 0.19 | - | - | - | - | |
| Other Unusual Items | - | - | - | 2.79 | -9.4 | -3.84 | |
| Pretax Income | -12.36 | -10.78 | -22.46 | -27.99 | -30.21 | -16.24 | |
| Net Income | -12.36 | -10.78 | -22.46 | -27.99 | -30.21 | -16.24 | |
| Net Income to Common | -12.36 | -10.78 | -22.46 | -27.99 | -30.21 | -16.24 | |
| Shares Outstanding (Basic) | 4 | 4 | 3 | 3 | 3 | 2 | |
| Shares Outstanding (Diluted) | 4 | 4 | 3 | 3 | 3 | 2 | |
| Shares Change (YoY) | 12.09% | 9.82% | 2.04% | 29.38% | 7.95% | 0.21% | |
| EPS (Basic) | -3.02 | -2.86 | -6.54 | -8.31 | -11.61 | -6.74 | |
| EPS (Diluted) | -3.02 | -2.86 | -6.54 | -8.31 | -11.61 | -6.74 | |
| Free Cash Flow | -5.58 | -9.56 | -15.84 | -19.12 | -13.08 | -8.43 | |
| Free Cash Flow Per Share | -1.36 | -2.53 | -4.61 | -5.68 | -5.02 | -3.50 | |
| EBITDA | -12.24 | -11.07 | -22.72 | -30.83 | -18.53 | -10.74 | |
| D&A For EBITDA | 0.2 | 0.22 | 0.2 | 0.12 | 0.08 | 0.06 | |
| EBIT | -12.44 | -11.29 | -22.92 | -30.95 | -18.61 | -10.8 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.